Opendata, web and dolomites

perGOla SIGNED

The first manufacturing process to obtain reduced graphene oxide at large-scale

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "perGOla" data sheet

The following table provides information about the project.

Coordinator
ABALONYX AS 

Organization address
address: FORSKNINGSVEIEN 1
city: OSLO
postcode: 373
website: www.abalonyx.no

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Norway [NO]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-10-01   to  2020-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ABALONYX AS NO (OSLO) coordinator 50˙000.00

Map

 Project objective

Despite its unique properties, graphene is relatively chemically inert, but its derivatives, graphene oxide (GO) and reduced graphene oxide (rGO) are much more reactive and attractive for industrial applications. rGO bears some remnant oxygen groups and holes that allow the possibility of functionalisation. Tailoring the oxygen content in rGO (C/O-ratio) controls its properties and modulates its performance, therefore, the capability of controlling the C/O-ratio is crucial.

The challenge is that rGO is not widely available at a commercial scale, even with a clear and identified market need for graphene derivatives. The Graphene Council identify 3 main barriers to commercialisation for graphene derivatives: cost of production; limitations of large-scale production and lack of quality assurance standards.

Abalonyx will address these challenges through the perGOla project by: 1) Reducing the production cost of rGO to 100-400 €/kg (from 2,500 €/kg) 2) Increasing the large-scale production of rGO up to ~4 kg/day (1,200 kg/year) through the first industrial automated manufacturing process. 3) Offering the most reliable rGO production line in the market since perGOla process will use GO manufactured in-house 4) Increasing the C/O- ratio up to 100, and tailoring the C/O-ratio and number of layers in the rGO

Abalonyx, leader in graphene sector, is a worldwide supplier of GO and rGO to research institutes, universities, SMEs such as Provexo, and “big players” such as ABB, Apple INC, and Tata Steel. 15% of our customers are recurrent customers.

We have strong support from end-users such as Qenos, an Australian composite manufacturer who is interested in large amounts of rGO, or European Thermodynamics Limited, who requires rGO at a cost-effective price for the development of thermal interface materials, will help us to accelerate the commercialisation of perGOla. Within 6-years of commercialization, we expect €25m of cumulative profit to achieve an ROI of 11.5.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PERGOLA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PERGOLA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

MEDIVAC (2019)

Machine learning software to design personalized neoantigen vaccines tailored to specific vaccine delivery systems

Read More  

RDNA (2019)

Empowering New Venture Growth - RDNA

Read More  

SIMCARE (2019)

SImulation-assisted Minimally invasive CAncer tREatment using the gosmart environment

Read More